参考文献/References:
[1]Krishnamurthi RV,Feigin VL,Forouzanfar MH,et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990-2010: findings from the global burden of disease study 2010[J]. Lancet Glob Health,2013,1(5):e259-281.
[2]Kamel H, Healey JS. Cardioembolic stroke[J]. Circ Res,2017,120(3):514-526.
[3]Chugh SS,Havmoeller R,Narayanan K,et al. Worldwide epidemiology of atrial fibrillation:a global burden of disease 2010 study[J]. Circulation,2014,129(8):837-847.
[4]张悦悦,蒋晨阳. 心房颤动卒中预防的非药物疗法进展[J]. 心血管病学进展,2018,39(1):6-10.
[5]Go AS,Hylek EM,Phillips KA,et al. Prevalence of diagnosed atrial fibrillation in adults:national implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation(ATRIA) Study[J]. JAMA, 2001,285(18):2370-2375.
[6]Halperin JL,Hankey GJ,Wojdyla DM,et al. Efficacy and safety of rivaroxaban compared with warfarin among elderly patients with nonvalvular atrial fibrillation in the Rivaroxaban Once Daily,Oral,Direct Factor Ⅹa Inhibition Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation(ROCKET AF)[J]. Circulation,2014,130(2):138-146.
[7]Connolly SJ,Wallentin L,Ezekowitz MD,et al. The long-term multicenter observational study of dabigatran treatment in patients with atrial fibrillation (rely-able) study[J]. Circulation,2013,128(3):237-243.
[8]Kirchhof P,Benussi S,Kotecha D,et al. 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS[J]. Eur Heart J,2016,37(38):2893-2962.
[9]Steinberg BA,Greiner MA,Hammill BG,et al. Contraindications to anticoagulation therapy and eligibility for novel anticoagulants in older patients with atrial fibrillation [J]. Cardiovasc Ther,2015,33(4):177-183.
[10]Chang SS,Dong JZ,Ma CS,et al. Current status and time trends of oral anticoagulation use among Chinese patients with nonvalvular atrial fibrillation: The Chinese Atrial Fibrillation Registry Study[J]. Stroke,2016,47(7):1803-1810.
[11]Piccini JP,Sievert H,Patel MR. Left atrial appendage occlusion:rationale,evidence,devices,and patient selection[J]. Eur Heart J,2017,38(12):869-876.
[12]Blackshear JL,Odell JA. Appendage obliteration to reduce stroke in cardiac surgical patients with atrial fibrillation [J]. Ann Thorac Surg,1996,61(2):755-759.
[13]Manning WJ,Silverman DI,Waksmonski CA,et al. Prevalence of residual left atrial thrombi among patients with acute thromboembolism and newly recognized atrial fibrillation[J]. Arch Intern Med,1995,155(20):2193-2198.
[14]Holmes DR,Reddy VY,Turi ZG,et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation:a randomised non-inferiority trial[J]. Lancet,2009,374(9689):534-542.
[15]Reddy VY,Doshi SK,Sievert H,et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation:2.3-year follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial [J]. Circulation,2013,127(6):720-729.
[16]Reddy VY,Sievert H,Halperin J,et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation:a randomized clinical trial[J]. JAMA, 2014,312(19):1988-1998.
[17]Holmes DR Jr,Kar S,Price MJ,et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy:the PREVAIL trial[J]. J Am Coll Cardiol,2014,64(1):1-12.
[18]Reddy VY,Doshi SK,Kar S,et al. 5-year outcomes after left atrial appendage closure:from the PREVAIL and PROTECT AF trials[J]. J Am Coll Cardiol,2017,70(24):2964-2975.
[19]Reddy VY,Mobius-Winkler S,Miller MA,et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: The ASAP study(ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology) [J]. J Am Coll Cardiol,2013,61(25):2551-2556.
[20] Boersma LV,Schmidt B,Betts TR,et al. Implant success and safety of left atrial appendage closure with the Watchman device:peri-procedural outcomes from the ewolution registry[J]. Eur Heart J,2016,37(31):2465-2474.
[21]Boersma LV, Ince H, Kische S, et al. Efficacy and safety of left atrial appendage closure with Watchman in patients with or without contraindication to oral anticoagulation:1-year follow-up outcome data of the ewolution trial[J]. Heart Rhythm,2017,14(9):1302-1308.
[22]Sievert H,Lesh MD,Trepels T,et al. Percutaneous left atrial appendage transcatheter occlusion to prevent stroke in high-risk patients with atrial fibrillation:early clinical experience[J]. Circulation,2002,105(16):1887-1889.
[23]Calvo N,Salterain N,Arguedas H,et al. Combined catheter ablation and left atrial appendage closure as a hybrid procedure for the treatment of atrial fibrillation[J]. Europace,2015,17(10):1533-1540.
[24]Swaans MJ,Post MC,Rensing BJ,et al. Ablation for atrial fibrillation in combination with left atrial appendage closure:first results of a feasibility study[J]. J Am Heart Assoc,2012,1(5):e002212.
[25]Phillips KP,Walker DT,Humphries JA. Combined catheter ablation for atrial fibrillation and Watchman? left atrial appendage occlusion procedures:five-year experience[J]. J Arrhythm,2016,32(2):119-126.
[26] Fassini G,Conti S,Moltrasio M,et al. Concomitant cryoballoon ablation and percutaneous closure of left atrial appendage in patients with atrial fibrillation[J]. Europace,2016,18(11):1705-1710.
[27] Liu FZ,Lin WD,Liao HT,et al. Mid-term outcomes of concomitant left atrial appendage closure and catheter ablation for non-valvular atrial fibrillation:a multicenter registry[J]. Heart Vessels,2019,34(5):860-867.
[28]Li X,Wen SN,Li SN,et al. Over 1-year efficacy and safety of left atrial appendage occlusion versus novel oral anticoagulants for stroke prevention in atrial fibrillation: a systematic review and meta-analysis of randomized controlled trials and observational studies[J]. Heart Rhythm,2016,13(6):1203-1214.
[29]Koifman E,Lipinski MJ,Escarcega RO,et al. Comparison of Watchman device with new oral anti-coagulants in patients with atrial fibrillation:a network meta-analysis[J]. Int J Cardiol,2016,205:17-22.
[30]Sahay S,Nombela-Franco L,Rodes-Cabau J,et al. Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation:a network meta-analysis from randomised trials[J]. Heart,2017,103(2):139-147.
[31]Osmancik P,Tousek P,Herman D,et al. Interventional left atrial appendage closure vs novel anticoagulation agents in patients with atrial fibrillation indicated for long-term anticoagulation (PRAGUE-17 study)[J]. Am Heart J,2017,183:108-114.
[32]Dukkipati SR, Kar S, Holmes DR, et al. Device-related thrombus after left atrial appendage closure[J]. Circulation,2018,138(9):874-885.
[33]Jalal Z,Dinet ML,Combes N,et al. Percutaneous left atrial appendage closure followed by single antiplatelet therapy:short- and mid-term outcomes[J]. Arch Cardiovasc Dis,2017,110(4):242-249.
[34]Sedaghat A,Schrickel JW,Andrie R,et al. Thrombus formation after left atrial appendage occlusion with the Amplatzer Amulet device[J]. JACC Clin Electrophysiol,2017,3(1):71-75.
[35]Plicht B, Konorza TF, Kahlert P, et al. Risk factors for thrombus formation on the Amplatzer cardiac plug after left atrial appendage occlusion[J]. JACC Cardiovasc Interv,2013,6(6):606-613.
[36]Fauchier L,Cinaud A,Brigadeau F,et al. Device-related thrombosis after percutaneous left atrial appendage occlusion for atrial fibrillation[J]. J Am Coll Cardiol,2018,71(14):1528-1536.
[37]Korsholm K,Nielsen KM,Jensen JM,et al. Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone for post-implant antithrombotic therapy[J]. EuroIntervention,2017,12(17):2075-2082.
[38]Enomoto Y,Gadiyaram VK,Gianni C,et al. Use of non-warfarin oral anticoagulants instead of warfarin during left atrial appendage closure with the watchman device[J]. Heart Rhythm,2017,14(1):19-24.
[39]Horstmann S,Zugck C,Krumsdorf U,et al. Left atrial appendage occlusion in atrial fibrillation after intracranial hemorrhage[J]. Neurology,2014,82(2):135-138.
[40]Weise FK,Bordignon S,Perrotta L,et al. Short-term dual antiplatelet therapy after interventional left atrial appendage closure with different devices[J]. EuroIntervention,2018,13(18):e2138-e2146.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(6):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(6):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(6):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(6):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(6):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(6):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(6):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(6):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(6):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(6):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[11]李亚会 黄从新.左心耳封堵术常见并发症及其防治[J].心血管病学进展,2021,(5):408.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.006]
LI YahuiHUANG Congxin.Common Complications of Left Atrial Appendage Occlusion and Its Prevention and Treatment[J].Advances in Cardiovascular Diseases,2021,(6):408.[doi:10.16806/j.cnki.issn.1004-3934.2021.05.006]
[12]柏懿璇 崔凯军.左心耳封堵术后装置相关血栓[J].心血管病学进展,2022,(5):407.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.006]
BAI Yixuan,CUI Kaijun.Device-Related Thrombus After Left Atrial Appendage Occlusion[J].Advances in Cardiovascular Diseases,2022,(6):407.[doi:10.16806/j.cnki.issn.1004-3934.2022.05.006]
[13]王璐 李耀东.TAVR合并心房颤动抗凝策略的研究进展[J].心血管病学进展,2022,(8):695.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.007]
WANG Lu,LI Yaodong.Anticoagulation Strategy in Patients After TAVR Complicated with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2022,(6):695.[doi:10.16806/j.cnki.issn.1004-3934.2022.08.007]
[14]魏志梁 孙雨可 尹月娇 孙守刚.心房颤动合并慢性肾脏病患者的左心耳封堵治疗研究进展[J].心血管病学进展,2022,(9):783.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.005]
WEI Zhiliang,SUN Yuke,YIN Yuejiao,et al.Left Atrial Appendage Closure in Patients with Atrial Fibrillation Complicated with Chronic Kidney Disease[J].Advances in Cardiovascular Diseases,2022,(6):783.[doi:10.16806/j.cnki.issn.1004-3934.2022.09.005]
[15]加依娜·加尔肯 汤宝鹏 周贤惠 李耀东 芦颜美.非瓣膜性心房颤动患者“一站式”手术策略的有效性和安全性:单中心经验[J].心血管病学进展,2022,(12):1141.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.019]
Jiayina Jiaerken,TANG Baopeng,ZHOU Xianhui,et al.Effectiveness and Safety of "One-Step" Procedure in Patients with Non-Valvular Atrial Fibrillation:A Single Center Experience?/html>[J].Advances in Cardiovascular Diseases,2022,(6):1141.[doi:10.16806/j.cnki.issn.1004-3934.2022.12.019]